Welcome to the Health Catalyst Third Quarter 2022 Earnings Conference Call. All participants are currently in listen-only mode, and we will open the floor for questions after the presentation. I would now like to turn the call over to Adam Brown, Senior Vice President of FP&A and Investor Relations. Please begin, Adam.

Good afternoon, and welcome to Health Catalyst's earnings conference call for the third quarter of 2022, which ended on September 30, 2022. My name is Adam Brown. I'm the Senior Vice President of Investor Relations and Financial Planning and Analysis for Health Catalyst. And with me on the call is Dan Burton, our Chief Executive Officer; and Bryan Hunt, our Chief Financial Officer. A complete disclosure of our results can be found in our press release issued today as well as in our related Form 8-K furnished to the SEC, both of which are available on the Investor Relations section of our website at ir.healthcatalyst.com. As a reminder, today's call is being recorded, and a replay will be available following the conclusion of the call. During today's call, we will make forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding trends, strategies, the impact of the COVID-19 pandemic and inflationary macroeconomic environment on our business and the results of operations, our pipeline conversion rates and our general anticipated performance of the business. These forward-looking statements are based on management's current views and expectations as of today and should not be relied upon as representing our views as of any subsequent date. We disclaim any obligation to update any forward-looking statements or outlook. Actual results may materially differ. Please refer to the risk factors in our Form 10-Q for Q2 2022 filed with the SEC on August 5, 2022, and our Form 10-Q for Q3 2022 that will be filed with the SEC. We will also refer to certain non-GAAP financial measures to provide additional information to investors. A reconciliation of these non-GAAP financial measures to their most comparable GAAP measures is provided in our press release. With that, let me turn the call over to Dan for his prepared remarks, and then Brian will subsequently provide his prepared remarks. Dan?

Thank you, Adam, and thank you to everyone who has joined us this afternoon. We are excited to share our third quarter 2022 financial performance, along with additional highlights from the quarter. I will begin today's call with some commentary on our third quarter 2022 financial results by sharing that we are pleased with the company's overall financial performance. Our Q3 2022 total revenue was $68.4 million, representing 11% growth year-over-year, and our adjusted EBITDA was a loss of $4.6 million, with these results beating the midpoint of our quarterly guidance on each metric. Additional financial highlights from the third quarter include our technology revenue of $44 million, representing 15% growth year-over-year and our adjusted overall gross margin of 51.2%, representing an increase of approximately 25 basis points year-over-year. Now let me highlight some additional items from the quarter. You will recall from our previous earnings calls that we measure our company's performance in the three strategic objective categories of improvement, growth and scale; and we'll discuss our quarterly results with you in each of these categories. The first category, improvement, is focused on evaluating our ability to enable our clients to realize massive, measurable improvements while also maintaining industry-leading client and team member satisfaction and engagement. Let me begin by sharing a few examples of client improvements from recently published case studies. First, as part of its population health strategy, WakeMed Health and Hospitals utilized our software, including our DOS data platform and healthcare.ai to meaningfully improve its patient access performance. Prior to implementing our solution, WakeMed knew that its patients often had trouble accessing its system, but it lacked the actionable data that would enable the identification, prioritization and management of improvement opportunities. Leveraging our technology, WakeMed can now visualize patients across key performance indicators, including referral conversion rates, schedule utilization, new patient visits, cancellations, no shows, visit types and patient portal activation rates. After learning from its data, WakeMed prioritized upgrading and improving its patient scheduling process, optimizing its patient referral process and increasing the number of new patients while simultaneously growing the number of WakeMed physician practices. In just one year, the combination of our Health Catalyst solution and the WakeMed team's efforts ultimately led to WakeMed increasing its revenue by over $25 million and achieving more than a 15% relative increase in its outpatient visits. Next, as part of a broader client relationship, Banner Health engaged in a tech-enabled outsourcing relationship with Health Catalyst related to their clinical chart abstraction needs, which included Health Catalyst hiring a portion of Banner's Charter Jackson team as rebadged Health Catalyst team members who continue to perform chart abstraction for Banner Health. Leveraging our DOS data platform to automate several components of the abstraction process, we effectively allowed Banner to lower its costs and improve its clinical chart abstraction efficiency while simultaneously improving the abstraction team member experience. This tech-enabled outsourcing relationship has resulted in Banner realizing hard dollar annual savings of over $750,000 in abstraction labor costs and registry costs saved. Additionally, this automation has allowed the clinical chart abstraction resources to support Banner's quality improvement initiative, including a 46% improvement in case submission accuracy for electronic clinical quality measures reporting and the identification of over 71,000 cases out of 225,000 that would have been submitted in error. Lastly, the team member engagement scores of the rebadged chart abstraction team have seen a 30% relative improvement. Also in the improvement category, we have been fortunate to receive multiple recent external recognitions related to our team member engagement. First, we are excited to have been named to Modern Healthcare's 2022 Best Places to Work list for the 10th year in a row. Additionally, we are pleased to have been recently named the Salt Lake Tribune's 2022 Top Workplaces in Utah, a list that is based solely on employee feedback, marking the ninth year in a row that we've achieved this distinction. Our next strategic objective category is growth, which includes beginning new client relationships while also expanding existing client relationships. In this category, let me first share that in September, we hosted our ninth annual Healthcare Analytics Summit, inclusive of our annual user conference. We were excited to hold this year's conference back in person in Salt Lake City, and we were energized by what we viewed as a highly successful growth-focused event that included over 1,000 attendees, representing more than 175 existing clients and prospective client organizations and included over 70 representatives from existing client organizations presenting their improvement case studies realized in partnership with Health Catalyst. As it relates to our current selling environment, our Healthcare Analytics Summit, along with numerous other existing client and prospective client conversations over the last quarter have given us hundreds of opportunities to listen and gather additional data and feedback related to the current growth environment. As a subset of those hundreds of interactions, I have personally had the opportunity over the past three months to visit face to face with the CEOs, COOs, CFOs, CIOs and other executives at 15 of our top 20 clients and over half of our top 50 clients, with our top 50 clients representing over two-thirds of our company's total recurring revenue under contract. These in-person meetings have been a significant recent focus of our team and of mine given our current end market dynamics as we strive to better understand our client challenges and to help ensure that we are offering solutions that help our clients overcome these challenges and succeed. I, along with our client and growth organizations, will continue these visits with our largest clients in the months ahead to ensure that we strengthen these relationships by offering solutions that enable both short-term and long-term success for our clients. As we have synthesized feedback from our clients and prospects, I would share that while we see both headwinds and tailwinds as it relates to our growth in Q4 and beyond, we are encouraged to see a meaningful increase in the size of our pipeline, particularly in those parts of our portfolio that offer near-term hard dollar cost savings. As it relates to headwinds, aligned with what we shared last quarter, our health system end market continues to experience meaningful financial strength, primarily due to significant increases in labor and supply costs without a commensurate increase in revenue, leading to substantial margin pressure. We anticipate this dynamic will persist for at least the next few quarters. The number one theme we heard at our Healthcare Analytics Summit was the significant financial pressure, and health systems' interest in leveraging technology and services solutions to help mitigate that pressure. Next, as shared on our last earnings call, in the first half of this year, we experienced an elongation in several of our sales cycles as many health systems temporarily paused purchasing decisions to give themselves time to realign their budgets with their updated financial outlook. Now as it relates to tailwinds, as we've continued through the second half of the year, most health care organizations we've spoken with have had the opportunity to work through a 2022 rebudgeting process that now aligns with their updated annual financial expectations, which we expect will enable more purchasing decisions by the end of this year relative to the first half of 2022. And we expect that those purchasing decisions will be largely focused on solutions that deliver hard dollar financial improvement in the near term. This gives us incremental confidence in our pipeline conversion expectations for the remainder of 2022. Second, as it relates to tailwinds, while financial strain has continued to pressure health system budgets, in our recent sales conversations, we have heard a strong acknowledgment from our clients that our portfolio includes solutions that directly reduce health systems' current financial pressure, especially related to the segments of our offering that have a clear near-term financial ROI such as our Financial Empowerment Suite, our Population Health Suite and our tech-enabled outsourcing offering. Coming out of this quarter, we feel highly energized that our offering, along with our partnership approach with clients is resonating with current and prospective clients, and that provides us with a high level of confidence in our Q4 and full year 2022 performance and guidance. The meaningful increase in the size of our pipeline that we have observed over the last 90 days, particularly in those solutions that offer near-term hard dollar client benefit, also encourages us as we look forward to the reacceleration of our bookings growth in 2023 and beyond even as we navigate a challenging macroeconomic and end-market environment. Lastly, related to tailwinds, my recent face-to-face conversations with senior executives at dozens of our largest clients has reinforced my conviction in the strength and strategic nature of those partnerships. I have confidence that these relationships will continue and expand well into the future. These updates inform an increase to our projected 2022 dollar-based retention and our forecasted revenue for full year 2022. Brian will cover the update to our 2022 revenue projection in a few minutes, and I'm happy to share that we now expect our 2022 dollar-based retention achievement level to be between 97% and 101%, an increase relative to the range we shared last quarter. This incremental confidence is driven by growth in our existing client expansion pipeline relative to prior expectations and a modest reduction in forecasted churn for 2022. The largest increase in expansion opportunities has come in the area of tech-enabled outsourcing. Related to our DOS subscription customer bookings metric, we are reaffirming our expectation to achieve mid- to high single digits net new DOS subscription customer additions in 2022. As it relates to our net new DOS subscription customer metric, a reminder that we typically experience seasonality in our new client bookings with Q2 and Q4 normally representing the majority of our sales aligned with health care organization fiscal years. This fourth quarter will also represent an important new client selling season as most fourth quarters have been for our company throughout its history. In terms of the mix of our Q4 new client pipeline, we do anticipate a few opportunities with new DOS light subscription clients that will begin at a lower price point than our historical average and will also include other newer platform offerings, including continued integration with the KPI Ninja platform component with significant upside opportunity over the medium to long term, which will enable us to get started with certain prospects while they navigate near-term budget constraints. Lastly, in the strategic objective category of growth, I wanted to first thank Patrick Nelli for his countless contributions to our company's success over the last 9 years as he transitions to a strategic adviser role. And I want to share my excitement for Kevin Freeman, recently appointed as our Chief Growth Officer; and Todd Bryant as our Chief Marketing Officer. Kevin and Tara bring decades of experience to their respective roles, and I will have overall responsibility for strategic growth functions at Health Catalyst. I am highly confident each of them will be instrumental in driving our success as we strive to reaccelerate our growth moving forward. Next, I would like to provide an update on a few of the strategic investment areas that we've covered on our last earnings call. Based on the multitude of client and prospect conversations that we have had over the last quarter, including at our Healthcare Analytics Summit, it is clear to us that there is high satisfaction with many aspects of Health Catalyst existing solutions, as clients and prospects are focused on the most effective ways to utilize our software and services to alleviate their near-term financial strains. We are continuing to make several strategic R&D investments in order to maintain our position as a market-leading data platform over the long term with a focus on providing our clients with a strong ROI over time, as we have continued to share these investment focus areas with our clients and prospects, including at our recent Healthcare Analytics Summit user group, the feedback was very enthusiastic and affirming of our R&D direction. As a reminder, our investment in our data platform scalability includes cloud-native, modern architecture capabilities with Snowflake enablement, elastic compute and event-driven processing. As we have previously shared, we have been investing in this initiative for the last couple of years. In terms of rolling these capabilities out to clients, one of our largest recent client additions is deployed in a cloud-native environment, and we have begun migrating one of our longest-standing on-premise clients to a similar cloud-native environment. More broadly, for existing clients, we are in the early stages of a migration process that we anticipate will take two to three years as our existing database infrastructure continues to function well for the vast majority of our clients. Individual migration decisions will be driven by the size of a client data footprint and their desire and readiness to transition. Also as a reminder, we have been investing in our technology's time-to-value capabilities, including standards-based data models, plug-and-play data acquisition enablement, enhanced data quality, embedded AI and machine learning capabilities and an extensible unified data model. We expect the bulk of this investment to be completed in 2023 with meaningful progress already made to date and with many of our clients currently benefiting from the results of these investments. Related to our strategic technology investments, let me also share my excitement for the recent appointment of Dave Ross as our Chief Technology Officer. Dave joined Health Catalyst in 2021 as part of our Twistle acquisition and was previously the Chief Technology Officer and Co-Founder of Twistle, leading all product development and engineering activities for over 10 years prior to Twistle being acquired by Health Catalyst. Dave brings a wealth of experience directly related to the strategic investments we are currently making in our technology, and I am confident he is the right leader to enable our success in this chapter of our company's growth. I would like to thank Brian Hinton for his 10 years of service, dedication and significant contributions to our company's mission and success in various technology leadership roles over the years. We wish Brian Hinton continued success in his future endeavors. Finally, let me share that as we continue to invest strategically in our software and services, we are strongly committed to balancing those investments in order to achieve the profitability targets we shared on our last earnings call. While we have certainly approached our cost reduction efforts to be consistent with the Health Catalyst way, as you will hear from Bryan shortly, we are pleased to be ahead of schedule relative to our prior cost reduction forecast, including for 2022. And as such, we are raising our adjusted EBITDA guidance for 2022. This is a strong signal of our commitment in 2022 and beyond to execute on our previously stated near- and midterm profitability and free cash flow targets. With that, let me turn the call over to Bryan.

Thank you, Dan. Before diving into our quarterly financial results, I want to echo what Dan shared and say that I'm pleased with our third quarter performance. I will now comment on our strategic objective category of scale. For the third quarter of 2022, we generated $68.4 million in total revenue. This total represents an outperformance relative to the midpoint of our guidance, and it represents an increase of 11% year-over-year. Technology revenue for the third quarter of 2022 was $44 million, representing 15% growth year-over-year. This year-over-year growth was driven primarily by recurring revenue from new client additions and from existing clients paying higher technology access fees as a result of contractual built-in escalators. Professional services revenue for Q3 2022 was $24.4 million, representing 4% growth relative to the same period last year. Overall, our Q3 2022 total revenue performance was slightly higher than our guidance contemplated primarily due to technology environment go-lives occurring on average, faster than anticipated and delayed timing of certain previously known churn events. For the third quarter of 2022, total adjusted gross margin was 51.2%. The representing an increase of approximately 25 basis points year-over-year. In the Technology segment, our Q3 2022 adjusted technology gross margin was 68.2%, a decrease of approximately 170 basis points relative to the same period last year. This year-over-year performance was mainly driven by continued costs associated with transitioning a portion of our client base to third-party cloud-hosted data centers in Microsoft Azure, which increases our hosting costs as well as increased support costs partially offset by existing clients paying higher technology access fees from contractual built-in escalators. In the Professional Services segment, our Q3 2022 adjusted professional services gross margin was 20.4%, representing an increase of approximately 40 basis points year-over-year and a decrease of approximately 610 basis points relative to the second quarter of 2022. This quarterly performance was in line with the expectations we shared on our last earnings call, mainly driven by lower utilization rates as compared to Q2, a result of higher per-client staffing levels than we anticipate at steady state. In Q3 2022, adjusted total operating expenses were $39.5 million. As a percentage of revenue, adjusted total operating expenses were 57.8%, which compares favorably to 60.3% in Q3 2021. Adjusted EBITDA in Q3 2022 was a loss of $4.6 million with this figure outperforming the midpoint of our guidance and comparing favorably to an adjusted EBITDA loss of $5.8 million in the third quarter of 2021. As a reminder, our Q3 operating expense is inclusive of approximately $3 million in expense related to our Healthcare Analytics Summit. Our adjusted net loss per share in Q3 2022 was a loss of $0.13. The weighted average number of shares used in calculating adjusted net loss per share in Q3 was approximately 54.3 million shares. Turning to the balance sheet. We ended the third quarter of 2022 with $380 million of cash, cash equivalents and short-term investments compared to $445 million at year-end 2021. Additionally, the face value of our outstanding convertible notes is a principal amount of $230 million and the net carrying amount of the liability component is currently $226.1 million. As it relates to our financial guidance for the fourth quarter of 2022, we expect total revenue between $66.9 million and $68.9 million and adjusted EBITDA losses between $2.1 million and $0.1 million. And for the full year 2022, this implies we are raising our full year revenue and adjusted EBITDA outlook. We now expect total revenue between $274 million and $276 million. At their respective midpoints, this represents an increase of $1.5 million compared to the full year revenue guidance we provided last quarter. We also expect adjusted EBITDA losses between $4 million and $2 million. At their respective midpoints, this represents an improvement of $2 million compared to the full year adjusted EBITDA guidance we provided last quarter. Now let me provide a few additional details related to our guidance expectations. In terms of Q4 revenue expectations, we anticipate that our technology revenue will be flat to slightly up sequentially and that our professional services revenue will be flat to slightly down sequentially. Next, in terms of our adjusted gross margin, we continue to anticipate that our adjusted technology gross margin will be in the high 60s for the fourth quarter. In the Professional Services segment, we anticipate that our professional services adjusted gross margin will be flat to slightly down as compared to Q3 2022. This is partially driven by lower anticipated utilization rates as a result of higher per-client staffing levels than we anticipate at steady state and partially driven by the anticipated mix of services to be delivered in the quarter. Lastly, as Dan mentioned, we are ahead of schedule on our cost reduction efforts for 2022, which enabled us to provide improved EBITDA guidance for 2022, with most of these restructuring events occurring in the second half of 2022 and a portion in early 2023. As a reminder, these restructuring efforts include pausing our investment in the life sciences adjacent market, realizing further SG&A savings as a result of M&A integration and an additional focus on sales efficiency, streamlining our expenses in other selected areas and further expanding our offshore delivery capabilities. Importantly, as it relates to our updated adjusted EBITDA full-year guidance, our current range is now consistent with the original full-year guidance that we provided entering 2022, demonstrating continued operating leverage in our business model despite lowered annual revenue guidance for 2022.

Thanks, Bryan. In conclusion, I would like to recognize and thank our committed and mission-aligned clients, and our highly engaged team members for their continued commitment to our mission in the midst of challenging circumstances. And with that, I will turn the call back to the operator for questions.

Our first question will come from Anne Samuel with JPMorgan.

Congrats on the results. You saw your cost improvements come in sooner than expected. I was hoping maybe you could talk a little bit about what you've done there so far and if there's still any areas left receiving.

Yes. Happy to address that. Thanks, Anne. We are pleased to see that our cost reduction objectives are ahead of schedule. And we have found in a couple of areas, particularly those SG&A areas, that we have some meaningful operating leverage. We mentioned in our prepared remarks some operating leverage as it relates to sales efficiency, and we will continue to pursue operating leverage moving forward. Importantly, as we also mentioned in our prepared remarks, we are going to continue to invest from an R&D perspective and some high-priority strategic investment areas, but we were pleased to find operating leverage in other parts of our operation and our operating expenses.

One thing I would add, Dan, to that to answer the question, Anne, is that some of the expense reductions you've seen kind of through Q3, some were working on in Q4. So there was not a full quarter's worth of kind of impact there yet in terms of our OpEx in Q4, and then we'll likely work through some in early 2023. And so as we get into our kind of final operating plan early next year, we'll provide specifics on more detail in terms of those reductions and our progress on EBITDA and cash flow.

That's great. Looking forward to hearing more color on that in the future. You also had some really encouraging commentary on the pipeline, and I was wondering if you could talk a little bit about, is that related to dollar retention since you were able to raise there or if you're also seeing a new client demand as well? And maybe what sort of the conversations are like with prospective customers right now just given the macro environment?

Yes. Happy to address that, Anne. So we do see meaningful encouraging signs with our existing clients, and we see some encouraging signs with new clients. I've spent the majority of my time focused on our existing clients but have spent some time with new clients as well and as mentioned in our prepared remarks, have spent and have the opportunity to have dozens of face-to-face interactions with C-suite executives at our largest clients. And what I would characterize as the environment is, number one, very much a focus on the financial pressure that these health systems are facing; but number two, a really productive series of discussions about us being part of that solution and being able to focus on those parts of our portfolio that really deliver near-term cost savings, near-term financial improvement. And that's the part of our pipeline where we've seen really meaningful expansion. And that's certainly been encouraging to us. So we're excited to see that progression take place, and we've been encouraged thus far. We'll have to see kind of how that exactly progresses. As you know, historically, we've typically had longer sales cycles of about 12 months. So we'll need to see exactly how that increased pipeline plays out over time, but we've certainly been encouraged to see so many of our existing clients and some of our prospective clients also recognize that we have parts of our portfolio that can really deliver for them in the near term from a financial perspective.

Our next question will come from Ryan Daniels with William Blair.

Congrats on the strong performance. Dan, one for you as a follow-up to your prepared comments. Besides the conversations you're having with clients, I'm curious how your organization can actually proactively analyze data to existing clients to help them uncover more near-term savings opportunities and to really propagate best practices between clients to ensure they're achieving improvements.

Yes. Thanks for the question, Ryan. And that's very much the approach that we're trying to take with each of our clients. There's sort of a multilayered way in which we can help them in the near term with their financial savings. The first layer is, as I mentioned just a minute ago and in our prepared remarks, often that direct near-term hard dollar savings that we can offer through something like tech-enabled outsourcing or through our Financial Empowerment Suite really helps our clients feel that assurance that those are the kinds of cost savings that they can build right into their budget in the near term. But that's not where we stop. So there's a second layer, which is that force multiplying impact, which is we not only look for the specific savings within areas where we might take more direct responsibility. But we're also looking much more broadly within the entirety of the health system setting where are there specific data-informed opportunities for improvement. That sometimes those take a little bit more time to go after, but they're actually enabled in terms of the ability to go after them by some of the efficiency gains that we gain in that first category. One example is outsourced chart abstraction, where almost everyone that is involved before we use our tech enablement is typically clinically trained, often nurses that are performing that manual chart abstraction in an expensive and an inefficient way. We leverage our technology, including the DOS data platform to automate certain steps in that process. That frees up clinical resources that can then be redeployed towards specific improvement projects that can be that force multiplying cost savings opportunity. And the client doesn't need to come up with incremental budget because they can just redeploy the savings to go after a larger opportunity from a cost perspective. And so that is an important part of that multilayered partnership that our clients get with us is, yes, the direct cost savings from some of the specific parts of our portfolio but also that second layer of force multiplied cost savings across their organization.

Just to add to that, Dan, the other component, Ryan, that we're working on in addition to the kind of team member contributions that Dan mentioned and the use of the technology to share data and best practices and uncover opportunities for savings, we're also working on continuing to utilize our case studies, our success stories across our client base to share with other clients and prospects and what's working well. We had a great opportunity to do that just recently at our Health Analytics Summit, where there were over 70 clients presenting those best practices, those results that they've achieved recently. And so that was just a great event to get additional feedback and to really promote and share the opportunities across our client and prospect base.

Great. That's super helpful color. I appreciate all that detail. And maybe one more question. As we think about the ability to offer hard dollar savings that clients can actually budget, obviously very attractive. That's going to drive your revenue retention or your pipeline conversion. I'm curious if you've contemplated doing more risk-based contracting given your ability to kind of prove this time and time again. Maybe that touches them forward. Is that occurring at conversations, either at the management level or client level?

You bet. Thanks for the question, Ryan. So we are open to multiple types of structures with our clients. What we're finding that they're most interested in right now and that first category that I talked about is just the ability to budget specific cost savings. Often, in our tech-enabled outsourced contracts, for example, we can write in something like up to 15% savings within the first nine months relative to what they've been spending and do that while rebadging their team members. And when we realize the efficiencies, we're able to often still retain those team members, just deploy them elsewhere, in other projects at the same client or in other projects with a different client. And so it's a win for the health system from a cost savings perspective, and it's a win for the team member as well in terms of their career path moving forward. We've been open to additional shared savings or shared benefit types of models. But often, we find that our clients just appreciate the simple straightforward nature of what we typically offer, which is just especially the CFOs appreciate that they can budget a specific dollar savings that happens on a very predictable time horizon in that first year. And then we typically agree to very modest annual increases that often expand the relative improvement in cost structure over time versus what they would have experienced themselves in terms of their own cost structure growing.

Our next question will come from Jessica Tassan with Piper Sandler.

I was hoping you could maybe talk a little bit about how the LifePoint deployment is going. And then just from kind of a tech architecture perspective, can you help us understand how HCAT works either with or alongside of the Google Health Cloud deployment that, I think, LifePoint sort of signed concurrently? Like where does one vendor start and the other end, if you will.

Thanks for the question, Jess. Yes, as we mentioned last quarter and published as a press release, we were really excited to welcome LifePoint as a client of Health Catalyst's. We were grateful to have them meaningfully participating in the health care analytics summit, and we're excited to see the deployment on schedule and moving along meaningfully well. It is a cloud-native deployment. And in this architecture that we referenced in our prepared remarks, part of the benefit of this architecture is its ability to integrate with other modules with other modular components that a client might prioritize as important to them. And so that was one of the elements that was appealing to LifePoint about the architecture that we shared with them, and that's working well so far.

The main focus in terms of our initial use case at LifePoint, Jess, is clinical improvement related to clinical variation, some population health use cases as well, all leveraging the data platform. And from what we understand, the initiative with Google is a little bit more so focused on that kind of front door to the health system, getting out to patients and managing patient records. So it is a different use case that we have there currently.

Got it. If I could ask one more question. Regarding tech-enabled outsourcing, we’ve noticed it coming up more frequently recently. Can you explain how it fits into our services or tech revenue? Is it classified as recurring revenue? What types of services are included in that offering?

Yes, absolutely. So we do classify the tech-enabled outsourcing as services revenue. And it's been one of the services offerings that we've offered now for 8 years. And so we have a meaningful track record and quite a bit of experience offering tech-enabled outsourcing to a number of our clients, starting with Allina Health years ago. Some of the areas where we have the most experience include outsourced chart abstraction, like we shared in the prepared remarks that Banner Health and others are leveraging and realizing meaningful cost savings. It is typically structured as a multiyear contract, often a 5- or longer-year contract of recurring revenue on the services side. One of the other benefits that we've seen over the last eight years is because we use our own technology to produce that meaningful savings, often up to 15% savings relative to what the client has been spending, we do require that in most cases, our clients remain current on their technology subscription. And so we found over time that the stickiness of the technology subscription is very strong, very significant in all of our relationships where we have tech-enabled outsourcing in place as well.

Right. Yes. And so there is, Jess, a component of both technology and services in terms of the revenue drivers there, as Dan mentioned. So the technology subscription, use of the data platform, increased utilization there hits the technology side. And then the kind of offering that Dan mentioned of analytics or chart abstraction hits more on the services side from a revenue standpoint.

Our next question will come from Elizabeth Anderson with Evercore ISI.

One of the things that struck me when you guys were speaking at, I think I hadn't heard this before, as you were talking about the delay of a certain churn event benefiting revenues. Is that sort of like a change in the churn event itself? Or is that sort of just a push out of that? I was wondering if you could just sort of give a few more details on sort of your expected timing there. That would be helpful.

Yes, absolutely. So Elizabeth, we have been encouraged and a couple of things that we mentioned in our prepared remarks. I mentioned that I have been encouraged to see the existing client pipeline expand meaningfully, and we've also seen a relative modest reduction in the forecasted churn that we were expecting in 2022. We've also experienced, as Bryan mentioned in some of his prepared remarks some delays in potential churn that we had forecasted. And sometimes, that results in just there being a delay. Other times, it results in the client making a different decision. And we appreciate the opportunity to have a little bit more time to explore how to move forward in the most positive way with our clients. So both of those dynamics are elements that we've observed.

Got it. That's really helpful. I noticed you mentioned that customers are increasingly focused on short-term ROI and hard dollar decisions. You also referenced some investments aimed at enhancing the ROI and the speed of the ROI on your core DOS platform. Could you elaborate on that a bit? I understand it may still be early in that process, but I would like to hear more about those investments.

Yes, absolutely, Elizabeth. So our clients are definitely focused on how can we alleviate our own financial pressures and what opportunities do we have, both with technology and with services that will enable that to occur. And we gave a few examples in our prepared remarks, for example, in the area of tech-enabled outsourcing, we've been investing in tech that more quickly automates certain processes that were manual. A good example of some of that tech includes the acquisitions recently of ARMUS and KPI Ninja. Importantly, KPI Ninja is becoming an important part of our data platform. And it does enable us, from a time-to-value perspective, to realize some of those automation steps faster than we otherwise could have. Likewise, when we think about the foundational value proposition of the data platform, we want to make sure that time to value is always really strong. And the investments that we're making in the cloud-native architecture speed up the implementation time and our ability to scale up in terms of the data that's flowing into the data platform much more quickly and much more significantly, which just opens up ROI use cases much sooner than they otherwise would be available to the client.

Got it. But you don't have a specific timeline on sort of like a new timeline. I know previously you talked about it sort of like more like a two-year period, you don't have a specific new period. You're just making improvement across the board as you guys see fit?

We are. We shared in our prepared remarks that we expect that most of the investment in this next iteration of our data platform will be completed in 2023. And then we'll be working with clients and migrating them to be able to take advantage of all those capabilities over the next couple of years.

And just to add to that, to your question, Elizabeth, there are ways that we are driving that hard dollar ROI savings a little more quickly than what would be typical with kind of an analytics platform deployment. And that is that based on focusing on those three areas that Dan mentioned of the Financial Empowerment Suite, the Pop Health Suite, the technical outsourcing, which can drive that budgeted savings more near term. And then in addition to that, we still have that kind of core analytics value proposition, where once you're using the data, you can identify myriad ways to drive additional costs or improvement work on top of that data. And we're trying to, again, speed up that component as well.

Our next question will come from Stephanie Davis with SVB Securities.

This is Anna standing in for Stephanie. We've observed some mixed signals regarding IT spending trends among providers, so I was hoping you could provide insights from your recent discussions with clients about where they are investing and where they are scaling back.

Yes. It's a great question. Thanks, Anna. We would observe, and I would personally observe just having completed dozens of these face-to-face discussions with CIOs as well as CEOs, COOs, CFOs, that, as we mentioned in our prepared remarks, there's a very significant focus on what solutions deliver near-term hard dollar financial results. And there's a definite shift away from what I might characterize as the more traditional sort of science project, and we're really excited about this new technology and you need to come up with new budget, and there's no guarantee as to whether it will produce anything from an ROI perspective. There's actually been a lot of that in health care over the years. And I have certainly heard over and over and over again our existing clients pivoting strongly away from those and in many cases, consolidating what remaining spend that they're prioritizing on fewer long-term partners like Health Catalyst. And we happen to also share a number of customers with Epic, and there are definitely another consolidation platform where we see our clients doing more and more with Epic, and we encourage that mindset and that strategy. Often, our clients are able to realize a much more significant ROI on the investment they've already made in those consolidation platforms, and we're fortunate Health Catalyst to be considered one of those consolidation platforms. We're fortunate to have a few elements of our portfolio that are specifically designed to deliver that near-term ROI. That is absolutely kind of 100% my conversations with C-Suite executives have been focused right on that ROI and making sure that all of their investments are going to produce a very measurable hard dollar ROI or they're not investing.

Got it. All right. And then as a follow-up, given the current labor market, can you give us an update on where you're recruiting from? And just how this evolved over time? And how are you ensuring that your incoming talent fill as adequate health care expertise?

Yes, absolutely. Great question. And we are seeing that as, I think, the broader industry experiences some more headwinds in terms of its financial performance. Certainly, we're finding that there's a little bit more equilibrium in terms of labor supply and labor demand. It's still challenging, but we have benefited Health Catalyst from a long-term multiyear, more than a decade focus on being a highly engaged employer and the best place to work. And so we continue to benefit from that. We continue to see turnover rates that are well below industry averages and very, very high engagement levels. So when we do have open positions at Health Catalyst, we benefit from the fact that we get many, many applicants for those positions and a very high conversion rate when we extend offers. That is a process where we will never be done, focusing on high team member engagement. But we have found that that's a benefit that Health Catalyst realizes, and it's one of the reasons why many of our clients are interested in tech-enabled outsourcing, where they've had a lot of difficulty from a hiring perspective and a retention perspective, and they see the results that Health Catalyst has achieved and believe that we can help them benefit from much higher engagement levels and much lower turnover levels as well.

Just to add to that, we are also focused, Anna, on, as we mentioned, driving additional efficiencies in areas like SG&A, in particular, on the services side and the like. But we are investing in certain areas as well. And so that's where a little bit more of the hiring, like ensuring that we have the right health care-specific talent comes in, is more so on the R&D side, in particular, related to our platform and other investments.

Our next question will come from Richard Close with Canaccord Genuity.

Congratulations. Dan, maybe expanding on tech outsourcing. I'm curious how you think about the company, the company's overall business longer term. And that is the mix between technology and professional services revenues longer term and then the gross margin profile of the company.

Yes. Great question, Richard. So as you will recall, because you were there when we went public 3.5 years ago, we talked as part of our IPO road show about the fact that services is a really important part of our overall solution set. And at the time of our IPO, we were closer to 50-50 in terms of the tech and services mix. Now over the next three years or so, we found that our tech revenue grew at a faster pace than our services revenue. And that happened for a variety of reasons, good reasons, and we expanded our tech portfolio to be much more compelling and much more comprehensive for clients. When I think forward to the next few years, I wouldn't be surprised if services catches up to what we experienced over the last few years from a tech revenue growth perspective in terms of getting back to closer to that balance of around 50-50 that we looked like when we went public. And that's how we messaged long term that we expected a really meaningful component of our business to come from both tech and services. We continue to believe that. And we also continue to focus on which elements of our portfolio help our clients be successful given what they're facing. And certainly, right now, we wanted to be transparent with the investment community that we're certainly seeing certain elements of our portfolio, now that includes technology, meaningful technology like our Financial Empowerment Suite, like our Pop Health Suite and even with tech-enabled outsourcing, we use DOS heavily and other components of our technology like ARMUS heavily to automate steps in the process for items like chart abstraction that would have otherwise been manual. And that's one of the reasons why we require that our clients that are using us for tech-enabled outsourcing stay current on their tech subscription for the data platform. And so even in cases where we might see a part of our services mix grow rapidly like tech-enabled outsourcing, it still pulls with it technology at a meaningful level.

Just to add to that, Richard, another area we are very focused on is managing and continuing to improve our operating leverage and EBITDA performance. You may have noticed some progress regarding our 2022 initiatives. We are particularly attentive to this from an SG&A perspective as we approach next year. We take our commitments to EBITDA and free cash flow seriously. Additionally, as Dan mentioned, we are observing a slight increase in our services pipeline. We will address that in Q4 and the first half of next year, but we will keep working to enhance our EBITDA and cash flow.

Okay. That's very helpful. And then you mentioned the investments in the platform over the last couple of years and expectation, a multiyear transition. Can you talk to us about like how you see the impact of that on the number of DOS clients that you expect to be signing over the next couple of years. Do you think people wait until the transition is fully GA, so to speak?

I don't think so. I do believe that with our existing clients, as we mentioned in our prepared remarks, we'll kind of be really thoughtful with those clients about what time frame makes the most sense. And as we mentioned, we've already begun that transition with one of our largest existing clients. And on the new client side, it's actually a lot more straightforward to start with the new technology, the new architecture because there's not a lot of legacy to migrate. And so with new clients, it's more straightforward in that regard. But we do believe that the feedback that we've received in terms of the architecture itself, its scalability, its modularity, it's very compelling, it's very interesting to both existing clients and new clients. So we're excited about that.

I believe the increase in DOS client additions will be influenced more by end market dynamics and the financial pressures on systems rather than by technology infrastructure, which we have been marketing over time. Can we align this platform use case with the immediate hard dollar ROI opportunity we discussed? I think it's also possible to focus on specific areas like the DOS light opportunity and then expand from there. Those will be the primary factors compared to the technology itself.

I want to highlight one important aspect, Richard, which is that I'm dedicating more time to our current clients. Our primary focus is to ensure that our existing clients achieve success. We're noticing a significant rise in growth opportunities with them, and I believe we will prioritize helping these clients succeed and fulfill their needs with Health Catalyst. Once we've addressed that, we will also explore adding new clients. This strategy will influence our evaluation of growth opportunities. As you are aware, Richard, there tends to be more efficiency in sales when growing with existing clients because of the established relationships we have. We will keep this in mind as we plan our growth path and the major opportunities to deepen our connections with current clients.

Our next question will come from Daniel Grosslight with Citi.

You mentioned you're seeing new opportunities in DOS light type pricing models. As we think about the mid- to high single-digit net DOS adds this year, what percent do you think will be on the DOS light type modeling? What's the pricing differential between that and the typical enterprise DOS subscription?

Yes, happy to take that, Daniel. So we mentioned in our prepared remarks that we might expect a few of that total number for the year to fall within that DOS light category. And we've shared previously that often DOS light, you can think of as starting at about half the price of a typical enterprise starting point, but we do expect most of our new DOS subscription clients in 2022 to be that enterprise type of starting point.

Got it. Okay. And on the net dollar-based retention of 97% to 101%, is that for both tech and professional services? Or can you kind of bifurcate that out as to the two?

It is overall. So it's an overall projection. And we haven't shared specifics, but we have shared some directional color over time. And we would share that consistent with what we shared just a couple of minutes ago and answer to another question, we are seeing that the part of our pipeline that's growing the fastest is tech-enabled outsourcing. And so that would push up the services component maybe a little higher than that overall average. And then the tech component may be just slightly lower than that overall range average.

Our next question will come from David Larsen with BTIG.

Congratulations on the good quarter. It sounds like attrition levels are improving and the pipeline is improving. Can you provide any color around bookings or backlog and signed deals like with respect to the back half of 3Q '22, what you're seeing so far in 4Q and how 2023 is shaping up?

Yes, happy to. So we are encouraged, David, as you mentioned, to see some improvement as it relates to what we had previously forecasted for churn and certainly a meaningful expansion in our existing client pipeline relative to what we had previously forecasted. Those are all encouraging signs. As we have shared before, Q2 and Q4 tend to be higher volume quarters than Q1 and Q3. And so we have fewer data points in terms of what we observed for Q3, but we were pleased with our bookings performance for Q3 and early in Q4 as well. As we mentioned in our prepared remarks, Q4 always represents an important meaningful part of the year from a sales perspective, both with new clients and with existing clients. And so we're focused on ensuring that we end that year strong. And we're encouraged by the progress that we're seeing thus far.

Yes, I think the only thing that I would add is the late-stage pipeline has continued to progress, David, such that we have high confidence in terms of our coverage for the expansion and new client side that we're working on.

Okay. Great. That's very helpful. And then just with the Life Sciences solution, DOS solution, is that delayed? Or have you decided to sort of not pursue that? Or could you pick it up, like say next year or 2 years from now? And then like can you talk about growth in your health plan customers? Would it be possible to create a DOS type of solution for health plans? We charge sort of a PMPM rate and you coordinate care with your largest hospital customers. It seems to me like there's a lot of demand there. We're seeing a lot of growth in entities like Evolent that service health plans. Just any thoughts there would be very helpful.

Yes. Happy to address both of those. So with regards to our Life Sciences solution, we have paused our go-to-market activities related to life sciences. I do believe and anticipate that perhaps in a couple of years, we'll come back to that solution set. But part of that decision was driven by the fact that, in our core market, we see significant opportunities to do more to help our clients be successful. And that leads to your second question as it relates to what we might offer to health plans. I think our primary focus since inception has been primarily focused on providers. Now many of our provider clients have also grown into the payer space, and we want to grow with them. But our primary focus is still on remaining very deeply aligned with providers and ensuring that we're helping them to be successful. And so our Pop Health offering, for example, is catered towards providers that are moving into the payer space or the health plan space, but it's, for example, very focused on keeping the patient at the center, keeping clinical improvement at the center. And that's not necessarily something that is always prioritized when you come in at first and foremost from a health plan perspective. So I think we're going to stay with our core focus on our core market being providers and ensuring that we're helping them in every way possible. But that does include helping them to expand into the payer space and be really effective and successful there.

Our next question will come from Cindy Motz with Goldman Sachs.

Congratulations on the quarter. I'm following up on the last question. I understand you're not providing guidance for 2023 at this time, but it seems you're optimistic about your bookings. It appears the client from last quarter was an isolated case. You've raised your net dollar retention guidance to between 97% and 101%. Do you anticipate maintaining that range into next year? Additionally, can you share any insights about how this year compares? Clearly, 2023 presents challenges, but do you expect the growth rate you were considering to improve for next year? I have a follow-up as well.

Yes. Thank you, Cindy, for the question. I would share that from a bookings perspective, we're certainly encouraged by the meaningful expansion in our existing client pipeline that we expressed in the prepared remarks. As you think about how that flows through into 2023, I would expect our dollar-based retention for 2023 to be meaningfully better than our dollar-based retention for 2022. We'll provide more of that color and guidance at our next earnings call. But certainly, we're encouraged by that. Now as you know, based on a recurring revenue business, it does take time for bookings strength and bookings improvement to translate to the P&L. And so as we shared previously, that'll take some time. And 2023, as a result, will still be meaningfully impacted by the fact that our 2022 bookings, while the second half is turning out to be more robust, meaningfully more robust than the first half, we're still for the year behind what we had originally projected. And so that will impact 2023 from a P&L perspective. But we do expect, based on what we're seeing, especially among our existing clients, and as I mentioned in the prepared remarks, having had opportunities to have face-to-face in-person discussions with the majority of our largest clients that they want to expand with us.

Yes. I think the way we think about it, Cindy, is what Dan said, we're booking this year in terms of dollar base retention rate is kind of the trough bookings year, which does lead to the revenue growth trough here on the P&L being 2023, in particular, the first half of 2023 as we get into next year. But as our bookings continues to improve and net retention improves, that will lead to the growth that we expect to reaccelerate in 2023 second half and then 2024 and beyond.

I just wanted to follow up, Bryan. You mentioned your focus on R&D while also working on improving the EBITDA margin. It seems like you're doing better this year, aiming for a reduced loss. So next year, will we be at a point where we can expect adjusted EBITDA to be positive? Also, do you still have an outlook on where you see margins going in the next few years, as you have indicated in the past?

Correct. Yes, there are no major updates regarding the EBITDA progression we expect in 2023. We anticipate about 300 basis points of EBITDA margin improvement. On our last call, we also mentioned a medium-term EBITDA target of 10% by 2025 and a long-term target exceeding 20%. There are no significant changes to that outlook. We remain encouraged by the progress we've made in 2022, and finalizing our plan for next year will be a key focus for us.

And just along those lines, we were encouraged to see that, in 2022, we're ahead of schedule with regards to cost reduction, and we will continue to make this a focus and certainly share more specific updates as it relates to this in our next earnings call for 2023.

Next, we have Jack Wallace with Guggenheim Securities.

Congrats on a really solid quarter. Just wanted to talk a little bit about some of those faster-to-burn, in-demand revenue opportunities you have with Population Health Suites, the tech-enabled outsourcing, Financial Empowerment Suites. Thinking about the top 50 clients that represented the majority of your revenue. How penetrated are those offerings inside of that base? And then what would be, if you could give us a loose number for, what the potential revenue opportunity is within those customers?

Yes, absolutely, Jack. So thank you for that question. I would say as it relates to the penetration within our top 50 or top 100 clients, our Financial Empowerment Suite is inclusive of a recent acquisition of Vitalware in the last two years and then a longer-standing solution that we've developed on the cost side with power costing and power labor. And both of those, though, are relatively recent elements in our portfolio. And so there's a great deal of opportunity for us to further penetrate the existing client installed base, even among our largest clients. And so a majority of those clients still have the opportunity for expansion opportunities and realizing the meaningful ROI from the Financial Empowerment Suite as well as our Pop Health suite. And so we're excited about that. And we're also focused with our existing clients, in particular, on enabling that cross-sell to be as easy as possible. And so as you may recall, in many cases, as our clients grow with us, so many of them choose to move more towards that all-access tech subscription, which has built in meaningful contractual escalators that are often in the double digits from a percentage growth perspective. And the way that they feel good about that is just the ability to add new modules like the Financial Empowerment Suite or the Pop Health suite that gives them even more value for that tech subscription. There are others of our clients, typically are smaller clients that are on more of a modular tech subscription where it's more of a step-up function of revenue opportunity, but more of our large clients are moving towards or have already moved towards that all-access subscription.

And then on the other component, the tech-enabled outsource side, I would just mention, Jack, again, there is ample opportunity with that offering as well in the analytics and chart abstraction side in terms of the upsell potential with our top 50, top 100 customers.

This does conclude our Q&A session. And I would now like to turn the floor back over to Dan Burton for any additional or closing remarks.

Thank you all for your continued interest in Health Catalyst, and we look forward to future discussions. Take care.

Thank you, ladies and gentlemen. This does conclude today's Health Catalyst Third Quarter 2022 Earnings Conference Call. Please disconnect your lines at this time, and have a wonderful day.